Published in Rev Recent Clin Trials on September 01, 2010
Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS One (2012) 1.03
Mixing the right hepatitis C inhibitor cocktail. Trends Mol Med (2010) 0.91
Potent inhibitors of hepatitis C core dimerization as new leads for anti-hepatitis C agents. Bioorg Med Chem Lett (2011) 0.89
The Future of HCV Therapy: NS4B as an Antiviral Target. Viruses (2010) 0.87
Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site. Antimicrob Agents Chemother (2011) 0.87
Small molecule pan-dengue and West Nile virus NS3 protease inhibitors. Antivir Chem Chemother (2011) 0.86
Current and Potential Treatments for Ubiquitous but Neglected Herpesvirus Infections. Chem Rev (2014) 0.80
Association Between ABCB1 (MDR1) Gene Polymorphism and Unresponsiveness Combined Therapy in Chronic Hepatitis C virus. Hepat Mon (2013) 0.78
Costs of a public health model to increase receipt of hepatitis-related services for persons with mental illness. Psychiatr Serv (2013) 0.77
IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin. J Med Virol (2012) 0.75
Identification of ligands that target the HCV-E2 binding site on CD81. J Comput Aided Mol Des (2013) 0.75
Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med (2005) 7.98
Effect of home testing of international normalized ratio on clinical events. N Engl J Med (2010) 5.36
Severe pneumonia due to adenovirus serotype 14: a new respiratory threat? Clin Infect Dis (2008) 3.10
High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS (2003) 2.65
siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Angew Chem Int Ed Engl (2007) 2.61
Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol (2003) 2.32
Ultrasensitive detection of rare mutations using next-generation targeted resequencing. Nucleic Acids Res (2011) 2.11
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med (2012) 1.96
Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trial. JAMA (2010) 1.71
Phylogeny of Zika Virus in Western Hemisphere, 2015. Emerg Infect Dis (2016) 1.68
HIV infection in the elderly. Clin Interv Aging (2008) 1.59
Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci U S A (2003) 1.56
Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). J Clin Microbiol (2004) 1.55
Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One (2013) 1.49
Novel targets for antiretroviral therapy: clinical progress to date. Drugs (2009) 1.25
Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med (2008) 1.23
Oseltamivir for treatment and prophylaxis of influenza infection. Expert Opin Drug Saf (2009) 1.19
Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. J Acquir Immune Defic Syndr (2009) 1.19
The effect of diagnosis with HIV infection on health-related quality of Life. Qual Life Res (2006) 1.18
Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS One (2013) 1.14
Role of environmental surveillance in determining the risk of hospital-acquired legionellosis: a national surveillance study with clinical correlations. Infect Control Hosp Epidemiol (2007) 1.12
Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations. PLoS One (2012) 1.11
Prevalence of HIV infection among inpatients and outpatients in Department of Veterans Affairs health care systems: implications for screening programs for HIV. Am J Public Health (2007) 1.10
Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis (2013) 1.09
Diagnosing invasive fungal disease in critically ill patients. Crit Rev Microbiol (2011) 1.08
A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy. Med Decis Making (2007) 1.05
Enhanced health event detection and influenza surveillance using a joint Veterans Affairs and Department of Defense biosurveillance application. BMC Med Inform Decis Mak (2011) 1.04
HIV testing of at risk patients in a large integrated health care system. J Gen Intern Med (2007) 1.03
Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS One (2012) 1.03
Is spinal tuberculosis contagious? Int J Infect Dis (2010) 1.00
Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med (2014) 0.99
One-year outcomes of community-acquired and healthcare-associated pneumonia in the Veterans Affairs Healthcare System. Int J Infect Dis (2011) 0.97
Health-related quality of life assessment after antiretroviral therapy: a review of the literature. Drugs (2013) 0.97
Effective detection of the 2009 H1N1 influenza pandemic in U.S. Veterans Affairs medical centers using a national electronic biosurveillance system. PLoS One (2010) 0.96
Determinants of the cost of health services used by veterans with HIV. Med Care (2011) 0.95
The Relationship Between HIV Infection and Cardiovascular Disease. Curr Cardiol Rev (2008) 0.94
Outcomes associated with a cognitive-behavioral chronic pain management program implemented in three public HIV primary care clinics. J Behav Health Serv Res (2012) 0.91
Influenza treatment and prophylaxis with neuraminidase inhibitors: a review. Infect Drug Resist (2013) 0.91
Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease. J Acquir Immune Defic Syndr (2009) 0.91
Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients. J Med Virol (2010) 0.87
Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/HCV-coinfection. J Med Virol (2012) 0.87
Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus. J Virol (2006) 0.85
Connection domain mutations in treatment-experienced patients in the OPTIMA trial. J Acquir Immune Defic Syndr (2010) 0.85
Clinically significant drug interactions in younger and older human immunodeficiency virus-positive patients receiving antiretroviral therapy. Pharmacotherapy (2011) 0.84
Frequency of HIV screening in the Veterans Health Administration: implications for early diagnosis of HIV infection. AIDS Educ Prev (2008) 0.83
HIV-1 RNA and viral load. Clin Lab Med (2002) 0.83
Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study). Clin Infect Dis (2005) 0.82
Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques. Antimicrob Agents Chemother (2010) 0.82
Proteomic analysis of serum cytokine levels in response to highly active antiretroviral therapy (HAART). J Proteome Res (2005) 0.82
An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. Control Clin Trials (2003) 0.82
Public health practice is not research. Am J Public Health (2014) 0.82
Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients. PLoS One (2013) 0.82
Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds. Int J Infect Dis (2009) 0.81
The concurrent validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS. Qual Life Res (2009) 0.81
Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients. J Infect Dis (2010) 0.81
Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease. J Acquir Immune Defic Syndr (2013) 0.80
Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States. Ann Intern Med (2016) 0.80
Dengue surveillance in Veterans Affairs healthcare facilities, 2007-2010. PLoS Negl Trop Dis (2013) 0.79
Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy. J Interferon Cytokine Res (2008) 0.79
Effect of treatment interruption and intensification of antiretroviral therapy on health-related quality of life in patients with advanced HIV: a randomized, controlled trial. Med Decis Making (2011) 0.79
Thrombocytopenia from combination treatment with oseltamivir and probenecid: case report, MedWatch data summary, and review of the literature. Pharmacotherapy (2009) 0.78
CD4 counts and mortality in virologically suppressed US veterans. J Int Assoc Provid AIDS Care (2013) 0.78
Case files from Stanford University Medical Center: the initial presentation of HIV-1 infection--where public and personal health meet. MedGenMed (2006) 0.78
Effect of management strategies and clinical status on costs of care for advanced HIV. Am J Manag Care (2014) 0.78
Comparative assessment of antimicrobial usage measures in the Department of Veterans Affairs. Infect Control Hosp Epidemiol (2012) 0.78
Interferon combination therapy for HIV/hepatitis C virus coinfection. Immunotherapy (2011) 0.77
Infectious complications in OIF/OEF veterans with traumatic brain injury. J Rehabil Res Dev (2009) 0.77
GBV-C viremia and clinical events in advanced HIV infection. J Med Virol (2013) 0.77
Successful management of disseminated Nocardia transvalensis infection in a heart transplant recipient after development of sulfonamide resistance: case report and review. J Heart Lung Transplant (2003) 0.76
Utilization and access to antiretroviral genotypic resistance testing and results within the US Department of Veterans Affairs. J Acquir Immune Defic Syndr (2006) 0.76
IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin. J Med Virol (2012) 0.75
The safety and tolerability of Z-100 in patients infected with HIV-1. Antivir Ther (2006) 0.75
Sudden sensorineural hearing loss associated with vardenafil. Pharmacotherapy (2010) 0.75
Evolution of genotypic resistance algorithms and their impact on the interpretation of clinical trials: an OPTIMA trial substudy. HIV Clin Trials (2007) 0.75
Use of dried clinical samples for storing and detecting influenza RNA. Influenza Other Respir Viruses (2011) 0.75
Representational fluency in HIV clinical practice: a model of instructor discourse. J Contin Educ Health Prof (2007) 0.75